Angiosarcoma is a rare, aggressive soft-tissue sarcoma with a high rate of recurrence and distant metastasis. Only a few cases of angiosarcoma involving the scalp have been reported in the literature. We describe a case involving a 75-year-old woman who presented to the emergency department at the Detroit Medical Center with multiple painful scalp lesions. She had had similar lesions intermittently for several years that apparently had responded to treatment with antifungal creams, but those occurring in the 6 months before her presentation had not responded to that therapy. The fi nal diagnosis was a metastatic angiosarcoma. The patient achieved complete remission following treatment with a combination chemotherapy regimen consisting of gemcitabine (1,500 mg/m 2 ) and docetaxel (50 mg/m 2 ) administered biweekly. The patient was free of disease at the 15-month follow-up. This regimen is well tolerated and should be considered, especially in elderly patients and patients with comorbid conditions who may not tolerate other chemotherapeutic regimens.
Introduction
Angiosarcoma is a rare, malignant, aggressive vascular tumor that accounts for 2% of soft-tissue sarcomas. 1 Soft-tissue tumors are rare, accounting for only 0.65% of newly diagnosed tumors. 2 Most angiosarcomas (approximately 60%) occur in the skin and soft tissues. 3 More than half of the reported cutaneous angiosarcomas have been located in the head and neck region. 4 However, only a few cases of angiosarcoma involving the scalp have been reported. [4] [5] [6] Angiosarcomas of the scalp are more common in elderly male Caucasians 4 and typically have an aggressive course.
Although the etiology of angiosarcomas is unknown, some of the associated risk factors include lymphedema, trauma, radiation exposure, fi stula of chronic osteomyleitis, herpes zoster, and exposure to arsenic oxide and vinyl chloride. The role of ultraviolet light exposure as a risk factor is questionable. 7 Patients with angiosarcoma in the head and neck region usually present with a history of a blue or purple macular, nodular, or plaque-like lesion of a few months' duration. These lesions are usually nontender and may feel either fi rm or spongy. The lesions are clinically undetectable and tend to have indistinct borders because they are frequently multicentric. The differential diagnosis, given the nonspecifi c nature of the clinical presentation, includes a variety of conditions, such as trauma, cellulitis, hemangioma, and fungal infection. 7 Angiosarcoma has a high tendency for both local recurrence and distant metastasis. The 5-year survival rate is less than 12%. 5 Certain variables-such as an external diameter greater than 5 cm, a mitotic rate greater than 3 HPF, a depth of invasion greater than 3 mm, recurrence, positive margins, and distant metastasis-have been shown to be associated with an adverse outcome. 3 The correct treatment modality for angiosarcoma depends on locoregional resectability of the lesion, as well as the presence or absence of distant metastasis. For small, well-localized tumors, wide local excision followed by radiation is the main therapeutic strategy. Recently, Mohs surgery has been shown to have favorable outcomes compared to wide local excision for these tumors. 5 Metastasis to regional lymph nodes can be managed with neck dissection and adjuvant radiation, provided there is no evidence of distant metastasis. 4 The use of chemotherapy as an adjuvant therapy to surgery and radiation has a questionable role, and that approach requires additional research. 8 In this article we report the clinical presentation and treatment of a patient with advanced angiosarcoma of the scalp, which responded with complete remission to a well-tolerated chemotherapy regimen of biweekly gemcitabine and docetaxel (GEMDOC).
Case report
A 75-year-old woman presented to the emergency department at the Detroit Medical Center with multiple painful lumps on her scalp that had progressively increased in size since she had noticed them approximately 6 months previously. She reported having had similar scalp masses during the previous several years that apparently had been successfully treated with antifungal creams, but those occurring in the 6 months preceding her presentation had not responded to that therapy. Examination revealed three violaceous, raised scalp lesions: a 6 × 6 cm lesion in the frontoparietal area, a 3 × 3 cm lesion in the right occipital area, and a 2 × 2 cm lesion in the left temporal area. Although these lesions are usually nontender, in our patient they were tender to palpation, and areas of alopecia were present at the sites of the masses. A mobile, left-sided level-III neck mass, approximately 1.5 cm in diameter, was also noted.
Fine-needle aspiration of the scalp mass revealed high-grade carcinoma with a high nucleus-to-cytoplasm ratio and prominent nuclei with marked pleomorphism. Computed tomography (CT) of the head showed multiple subcutaneous scalp lesions that enhanced with contrast, as well as heterogeneously enhancing and necrotic lymph nodes at level II and level III on the left side, measuring up to 1.9 × 1.2 cm. Magnetic resonance imaging (MRI) of the head also showed enhancing subcutaneous lesions on T1 signal (fi gure 1) and an increased signal on T2 images. Positron emission tomography (PET) showed an abnormal increased tracer uptake in the three areas of the scalp previously identifi ed by MRI. Further, three focal areas of increased uptake were noted along the left internal jugular chain.
A defi nitive diagnosis of angiosarcoma of the scalp was made after excisional biopsy of one of the lesions under local anesthesia. Given the extensiveness of the sarcoma, with multiple dermal metastases, chemotherapy alone was recommended, and the patient was started on gemcitabine and docetaxel. This regimen consisted of 1,500 mg/m 2 IV gemcitabine, administered over 30 minutes, and 50 mg/m 2 IV docetaxel, administered over 60 minutes. Before the infusion was started, the patient was premedicated with 1 mg IV granisetron, 20 mg IV dexamethasone, 50 mg IV diphenhydramine, and 50 mg IV ranitidine. The chemotherapy cycles were repeated every 14 days and were exceedingly well tolerated by this elderly patient, who experienced no side effects other than alopecia and mild fatigue.
After 6 months of therapy, the patient achieved a complete response based on both clinical examination and radiologic examination (CT of the head and PET scan). At her 15-month postchemotherapy follow-up, the patient continued to be in complete remission, with no physical or radiologic evidence of recurrence (fi gure 2).
Discussion
Angiosarcoma is an aggressive soft-tissue sarcoma. Given its rarity, current treatment recommendations are mainly based on studies involving small series of patients. Although the recommended treatment for localized angiosarcoma is generally surgical, treatment with chemotherapy alone is recommended in the presence of metastasis. Several series have studied the role of chemotherapy in treatment of angiosarcomas (table) .
Fata et al found that 8 of 9 patients with angiosarcoma of the scalp treated with paclitaxel had a major response (4 had a complete response). 1 Their study was part of a phase II trial of the role of paclitaxel in the treatment of soft-issue sarcomas. Chemotherapy regimens includ-ing adjuvant doxorubicin were found to signifi cantly improve the distant recurrence-free time in a sarcoma meta-analysis collaboration. 9 Pawlik et al showed that 4 of 12 patients who were alive and free of disease at the end of follow-up were those who had been given chemotherapy as a salvage treatment. 10 Various chemotherapeutic agents were used in their study, including systemic interferon alfa-2b, cyclophosphamide, paclitaxel, 5-fl uorouracil, cisplatin, and etoposide.
Several researchers have studied the use of gemcitabine for the treatment of angiosarcoma. Merimsky et al reported a case involving a patient with angiosarcoma resistant to other chemotherapeutic agents who had a minimal response to gemcitabine. 11 Leu et al 12 and Bay et al 13 studied the role of gemcitabine and docetaxel in treating advanced angiosarcoma. While Leu et al 12 showed a positive outcome, with 2 of 4 patients having a complete response and 1 patient having a partial response, Bay et al 13 showed less positive results, with a 10.4% overall response. Lydiatt et al showed that doxorubicin used along with radiation therapy to treat unresectable angiosarcoma of the head and neck yielded poorer results than surgery. 14 Because the combination of gemcitabine and docetaxel had been found to have activity in soft-tissue sarcomas, 12 we used the gemcitabine and docetaxel regimen for the treatment of metastatic angiosarcoma in our patient. The regimen was given biweekly because of the patient's advanced age and comorbidities. This case was unique in that the patient presented with multiple scalp masses that were extremely tender upon palpation. The diagnostic delay of several years, during which time our patient's sarcoma had been treated with antifungal creams, might have contributed to the extensive nature of the disease and might have explained the multiple dermal metastases. Thus, this case illustrates the need to maintain a high index of suspicion for malignancy in persistent, nonhealing cutaneous lesions. The 5-year survival rate for patients with metastatic angiosarcoma is reported to be approximately 12%. 5 Given this dismal prognosis and the lack of a standard chemotherapeutic regimen for this disease, we think it is important to report our patient's excellent response to the gemcitabine and docetaxel regimen. The dramatic resolution of her advanced disease should stimulate further investigation of this regimen in the treatment of angiosarcoma.
